GlassScriptPhysician profile
Jamis Gouge
NPI 1750777355
$1,492.22
in general payments reported to CMS, 2019-2025
14 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $624 · 2022: $145 · 2023: $533 · 2024: $42.87 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $374.45 | 2021 | |
| Glaxosmithkline, LLC. | $246.73 | 2023 | Jemperli, Ojjaara |
| Janssen Pharmaceuticals, INC | $150.97 | 2021-2022 | |
| Pulmonx Corporation | $147.74 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $124.99 | 2023 | |
| Kite Pharma, INC. | $124.07 | 2023 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $77.75 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $68.84 | 2021-2023 | Ultomiris |
| Melinta Therapeutics, LLC | $55.91 | 2021 | |
| Intuitive Surgical, INC. | $42.87 | 2024 | |
| Ucb, INC. | $22.80 | 2022 | |
| La Jolla Pharmaceutical Company | $22.26 | 2023 | Xerava |
| Aurinia Pharma U.S., INC. | $16.98 | 2022 | |
| Pfizer INC. | $15.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamis Gouge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.